Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Monday 27 January, 2020

Nestle SA

Nestl� acquires Zenpep

RNS Number : 9781A
Nestle SA
27 January 2020
 

Nestlé Press Release

 

Vevey/Switzerland, January 27, 2020

 

 

Nestlé acquires Zenpep, expanding its medical nutrition business

 

Nestlé today announced that it has entered into an asset purchase agreement with Allergan to acquire the gastrointestinal medication Zenpep. This move aims to expand the company's medical nutrition business and complement its portfolio of therapeutic products.

 

Zenpep, available in the United States, is a medication for people who cannot digest food properly because their pancreas does not provide enough enzymes to break down fat, protein, and carbohydrates. Zenpep's 2018 net sales were USD 237 million.

 

"Nestlé's acquisition of Zenpep is a strategic decision that will enhance our growing medical nutrition portfolio," said Greg Behar, CEO of Nestlé Health Science. "This is a significant opportunity for our business in the United States to add a complementary product to our existing range of nutrition products that support food ingestion, digestion and absorption. We have extensive experience in Zenpep's therapeutic areas of digestive diseases through our medical nutrition business and will leverage those capabilities as we grow this new business."

 

The deal is expected to be finalized concurrent with the merger of Allergan and AbbVie. Financial details of this acquisition are not being disclosed.

 

Nestlé will take ownership of Zenpep upon closing the transaction, with customary transition support from the seller.

 

"Within our medical nutrition business, we work directly with healthcare professionals to educate them about our products that are used in hospitals, home healthcare, and clinics," said Anna Mohl, Business Executive Officer of Nestlé Health Science USA. "We are excited to leverage our broad capabilities and expand our team to drive rapid growth of this new acquisition. We look forward to welcoming all Zenpep employees who will join our team."

 

Note to the Editors:

Zenpep is for patients with Exocrine Pancreatic Insufficiency (EPI) who cannot digest food properly because their pancreas does not provide enough enzymes to break down fat, protein, and carbohydrates. It is in the class of Pancreatic Enzyme Replacement Therapies (PERTs) containing a mixture of digestive enzymes (lipases, proteases, and amylases) intended to help the body use essential macronutrients from food.  Patients with EPI need to take PERTs at every meal or snack to assure proper absorption of nutrients, or they risk being malnourished, underweight or experiencing gastrointestinal symptoms.

 

 

Contacts

 

Media                      Christoph Meier            Tel.: +41 21 924 22 00

                               Jacquelyn Campo          Tel.: +41 79 598 11 63

Investors                 Luca Borlini                   Tel.: +41 21 924 38 20


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
STRKKOBNABKKNDB

a d v e r t i s e m e n t